Gunderson Capital Management Inc. Buys Shares of 36,813 Astera Labs, Inc. (NASDAQ:ALAB)

Gunderson Capital Management Inc. purchased a new position in shares of Astera Labs, Inc. (NASDAQ:ALAB) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 36,813 shares of the company’s stock, valued at approximately $4,876,000. Astera Labs accounts for about 2.4% of Gunderson Capital Management Inc.’s investment portfolio, making the stock its 17th biggest position.

Other hedge funds have also made changes to their positions in the company. Strategic Blueprint LLC increased its position in Astera Labs by 3.6% in the third quarter. Strategic Blueprint LLC now owns 5,684 shares of the company’s stock worth $298,000 after buying an additional 195 shares during the period. GAMMA Investing LLC lifted its position in Astera Labs by 78.3% in the 4th quarter. GAMMA Investing LLC now owns 510 shares of the company’s stock valued at $68,000 after purchasing an additional 224 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Astera Labs by 5.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,284 shares of the company’s stock valued at $277,000 after purchasing an additional 284 shares during the period. ORG Wealth Partners LLC bought a new position in Astera Labs in the 4th quarter worth about $42,000. Finally, Hollencrest Capital Management acquired a new stake in shares of Astera Labs in the third quarter valued at approximately $26,000. Institutional investors own 60.47% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Northland Capmk lowered Astera Labs from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 2nd. Citigroup initiated coverage on shares of Astera Labs in a research note on Monday, November 18th. They set a “buy” rating and a $120.00 price objective on the stock. Stifel Nicolaus increased their target price on shares of Astera Labs from $100.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Morgan Stanley boosted their price target on shares of Astera Labs from $94.00 to $142.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. Finally, Craig Hallum increased their price objective on shares of Astera Labs from $75.00 to $105.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $105.75.

Astera Labs Price Performance

ALAB opened at $127.19 on Tuesday. The business has a fifty day simple moving average of $116.88 and a 200-day simple moving average of $74.77. Astera Labs, Inc. has a fifty-two week low of $36.22 and a fifty-two week high of $147.39.

Astera Labs (NASDAQ:ALAB) last released its quarterly earnings results on Monday, November 4th. The company reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.17 by $0.06. The business had revenue of $113.10 million during the quarter, compared to analyst estimates of $97.50 million. Astera Labs had a negative return on equity of 15.57% and a negative net margin of 30.69%. The company’s revenue for the quarter was up 47.1% compared to the same quarter last year. As a group, equities analysts expect that Astera Labs, Inc. will post -0.45 EPS for the current year.

Insider Transactions at Astera Labs

In other news, CFO Michael Truett Tate sold 16,000 shares of Astera Labs stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $117.84, for a total transaction of $1,885,440.00. Following the transaction, the chief financial officer now owns 1,412,888 shares in the company, valued at approximately $166,494,721.92. The trade was a 1.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Philip Mazzara sold 2,513 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $90.81, for a total value of $228,205.53. Following the transaction, the general counsel now directly owns 248,745 shares in the company, valued at $22,588,533.45. The trade was a 1.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,690,452 shares of company stock valued at $167,581,256 over the last ninety days.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.